Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Artemisinin combination therapy (ACT) with artemether lumefantrine (AL) is currently the first line treatment policy in Tanzania. AL is an efficacious drug that also has the capacity to reduce malaria transmission to mosquitoes. Nevertheless, there is concern about the development of parasite resistance against AL and there have been very few clinical trials that compared different ACT regimens. A recent clinical trial shows that the combination of dihydroartemisinin-piperaquine (DP) may be more efficacious than AL and may have a more pronounced beneficial effect on post-treatment malaria transmission. Screening for molecular markers that are related to parasite susceptibility to ACT drugs and to post-ACT treatment malaria transmission can assist in preventing the development and spread of ACT resistance.

In the current study, the investigators compared AL and DP for the treatment of uncomplicated malaria. The investigators endpoints are

* clinical efficacy
* post-treatment gametocytaemia by molecular techniques
* post-treatment malaria transmission.


Options:
A: Arm Label: Dihydroartemisin-piperaquine; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisin-piperaquine | Arm Label: Mefloquine + Artesunate (MAS3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine + Artesunate | Intervention Type: DRUG; Name: Dihydroartemisin-piperaquine; Assigned to Arm(s): Dihydroartemisin-piperaquine | Intervention Type: DRUG; Name: Mefloquine + Artesunate; Assigned to Arm(s): Mefloquine + Artesunate (MAS3)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amodiaquine-artesunate (ASAQ) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: dihydroartemisinin-piperaquine (DHAPQ) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: artemether-lumefantrine (AL) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS) | Intervention Type: DRUG; Name: amodiaquine-artesunate (ASAQ); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine (DHAPQ); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: artemether-lumefantrine (AL); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS); Assigned to Arm(s): 4
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Trimethoprim-sulfamethoxazole | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Trimethoprim-sulfamethoxazole; Assigned to Arm(s): A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-Lumefantrine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: Artemether-Lumefantrine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): 2

Answer: D